secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125376
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort
-------------------------------------------------------------------------------

- Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.
- Q3 operating loss $16.4M vs $18.2M in Q3 2023; R&D expenses $13.8M, G&A $3.8M.
- BDC-3042 Phase 1 advanced to 10 mg/kg cohort; data update expected H1 2025.
- BDC-4182 on track for clinical trial start in Q2 2025; preclinical data at SITC.
- Collaboration revenue $1.1M, down from $2.5M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/0000950170-24-125376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/bolt-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer